Tsukasa Yoshida Hiroshi Yaegashi Ren Toriumi Suguru Kadomoto Hiroaki Iwamoto Kouji Izumi Yoshifumi Kadono Hiroko Ikeda Atsushi Mizokami
10.3389/fonc.2022.912490
Front Oncol
2022 Sep 16;12:912490.
immune checkpoint inhibitor (ici) metastatic castration-resistant prostate cancer (mcrpc) microsatellite instability-high (msi-high) neuroendocrine differentiation (ned) pembrolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/36185251/
Case Reports
PMC9523122
36185251
Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
2022